<DOC>
	<DOCNO>NCT02791191</DOCNO>
	<brief_summary>The main purpose study evaluate safety effect brain tau study drug LY3202626 participant mild Alzheimer 's disease ( AD ) dementia .</brief_summary>
	<brief_title>A Study LY3202626 Disease Progression Participants With Mild Alzheimer 's Disease Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Present mild AD dementia base National Institute Aging ( NIA ) Alzheimer 's Association ( AA ) disease diagnostic criterion determine qualified clinician approve Sponsor designee . MiniMental State Examination score 20 26 inclusive screen visit . Has florbetapir PET scan consistent presence amyloid pathology screen . Significant neurological disease affect central nervous system ( CNS ) , AD , may affect cognition ability complete study , include limited , dementias , serious infection brain , Parkinson 's disease , multiple concussion , epilepsy recurrent seizure ( except febrile childhood seizure ) . Ocular pathology significantly limit ability reliably evaluate vision retina . Use strong inducer cytochrome P450 3A ( CYP3A ) within 30 day baseline . Sensitivity florbetapir ¹⁸FAV1451 . Contraindication MRI PET poor venous access blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>BACE inhibitor</keyword>
</DOC>